LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study

• Chun Wu,
• Yanhua Hu,
• Ignacio Sanz,
• Shalabh Singhal,
• J Michelle Kahlenberg,
• Jin Hyang Kim,
• Ian M Catlett

Affiliations

Chun Wu

3Informatics and Predictive Sciences, Bristol Myers Squibb, USA

Yanhua Hu

3Informatics and Predictive Sciences, Bristol Myers Squibb, USA

Ignacio Sanz

2Rheumatology, Emory University, USA

Shalabh Singhal

5Clinical Development, Bristol Myers Squibb, USA

J Michelle Kahlenberg

1Rheumatology, University of Michigan, USA

Jin Hyang Kim

4Translational Bioinformatics, Bristol Myers Squibb, USA

Ian M Catlett

6Translational Medicine, Bristol Myers Squibb, USA